Fertility startup Inito wants to use AI-designed antibodies to expand at-home health tests
PositiveArtificial Intelligence
- Inito has successfully raised $29 million in funding aimed at developing AI-engineered antibodies to enhance at-home health testing capabilities. This investment will facilitate the introduction of new tests and improve the accuracy of existing ones, positioning Inito at the forefront of health technology innovation.
- The funding is crucial for Inito as it seeks to expand its product offerings and solidify its market presence in the rapidly evolving health tech sector. By leveraging AI technology, Inito aims to provide more reliable and accessible health testing solutions to consumers.
- This development reflects a broader trend in the health technology industry, where companies are increasingly utilizing artificial intelligence to innovate and streamline processes. Similar ventures, such as Onepot AI's recent funding for drug creation, highlight a growing investment in AI-driven solutions across various sectors, emphasizing the transformative potential of technology in healthcare and pharmaceuticals.
— via World Pulse Now AI Editorial System




